Zhou Qiang-Ping, Li Xiu-Jiang
Department of Emergency Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
Dose Response. 2019 Nov 20;17(4):1559325819889814. doi: 10.1177/1559325819889814. eCollection 2019 Oct-Dec.
The relationship between pretreatment C-reactive protein to albumin ratio (CAR) and colorectal cancer (CRC) prognosis has been extensively studied in various tumors. However, little is known on CAR and its association with prognosis in CRC. This study aims to investigate the prognostic value of pretreatment CAR in CRC.
We conducted a systematic search of MEDLINE, EMBASE, and Cochrane Library databases for eligible studies evaluating the associations of CAR with survival and/or clinicopathology of CRC. Overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), and clinicopathological features were synthesized and compared.
Nine studies including 3431 patients were analyzed in this meta-analysis. Pooled results showed that elevated pretreatment CAR was associated with poor OS (pooled hazards ratio [HR]: 2.18, 95% confidence interval [CI]: 1.70-2.78, < .001) and DFS/RFS (pooled HR: 2.36, 95% CI: 1.40-3.98, < .001). Moreover, elevated pretreatment CARs were correlated with male patients, large tumor diameter, late III-IV tumor node metastasis stage tumors, high serum carcinoembryonic antigen and carbohydrate antigen 19-9, and presence of lymphatic invasion and venous invasion.
Elevated pretreatment CAR could be an adverse prognostic indicator in patients with CRC.
预处理C反应蛋白与白蛋白比值(CAR)和结直肠癌(CRC)预后之间的关系已在各种肿瘤中得到广泛研究。然而,关于CAR及其与CRC预后的关联知之甚少。本研究旨在探讨预处理CAR在CRC中的预后价值。
我们对MEDLINE、EMBASE和Cochrane图书馆数据库进行了系统检索,以查找评估CAR与CRC生存和/或临床病理特征关联的合格研究。综合并比较总生存期(OS)、无病生存期(DFS)、无复发生存期(RFS)和临床病理特征。
本荟萃分析纳入了9项研究,共3431例患者。汇总结果显示,预处理CAR升高与较差的OS(汇总风险比[HR]:2.18,95%置信区间[CI]:1.70-2.78,P<.001)和DFS/RFS(汇总HR:2.36,95%CI:1.40-3.98,P<.001)相关。此外,预处理CAR升高与男性患者、肿瘤直径大、肿瘤结节转移处于晚期III-IV期、血清癌胚抗原和糖类抗原19-9水平高以及存在淋巴浸润和静脉浸润相关。
预处理CAR升高可能是CRC患者的不良预后指标。